PRA Health Sciences (NASDAQ:PRAH) was downgraded by equities researchers at BidaskClub from a “strong-buy” rating to a “buy” rating in a report released on Friday.

PRAH has been the subject of a number of other research reports. Zacks Investment Research cut PRA Health Sciences from a “buy” rating to a “hold” rating in a report on Friday, September 15th. SunTrust Banks reissued a “buy” rating and set a $101.00 price target on shares of PRA Health Sciences in a report on Friday, October 27th. KeyCorp reissued a “buy” rating and set a $93.00 price target (up previously from $86.00) on shares of PRA Health Sciences in a report on Monday, October 30th. Mizuho set a $87.00 price target on PRA Health Sciences and gave the stock a “buy” rating in a report on Friday, December 1st. Finally, Robert W. Baird reissued a “buy” rating and set a $88.00 price target on shares of PRA Health Sciences in a report on Monday, October 9th. One equities research analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. PRA Health Sciences currently has an average rating of “Buy” and an average price target of $91.92.

PRA Health Sciences (PRAH) opened at $90.39 on Friday. The firm has a market capitalization of $5,731.16, a price-to-earnings ratio of 50.50, a price-to-earnings-growth ratio of 1.26 and a beta of 0.41. The company has a quick ratio of 1.01, a current ratio of 1.01 and a debt-to-equity ratio of 1.38. PRA Health Sciences has a fifty-two week low of $54.08 and a fifty-two week high of $92.84.

PRA Health Sciences (NASDAQ:PRAH) last announced its quarterly earnings data on Wednesday, October 25th. The medical research company reported $0.88 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.85 by $0.03. PRA Health Sciences had a return on equity of 21.66% and a net margin of 5.64%. The firm had revenue of $494.55 million during the quarter, compared to analysts’ expectations of $477.89 million. During the same period in the previous year, the firm earned $0.64 EPS. The company’s quarterly revenue was up 23.7% compared to the same quarter last year. equities research analysts anticipate that PRA Health Sciences will post 3.2 earnings per share for the current fiscal year.

In other PRA Health Sciences news, Director Matthew P. Young sold 5,115 shares of the company’s stock in a transaction dated Thursday, November 16th. The stock was sold at an average price of $79.90, for a total value of $408,688.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP David W. Dockhorn sold 72,850 shares of the company’s stock in a transaction dated Friday, December 28th. The stock was sold at an average price of $90.83, for a total value of $6,616,965.50. Following the completion of the transaction, the executive vice president now directly owns 72,850 shares of the company’s stock, valued at approximately $6,616,965.50. The disclosure for this sale can be found here. In the last ninety days, insiders sold 150,815 shares of company stock valued at $13,642,620. Insiders own 2.10% of the company’s stock.

A number of institutional investors and hedge funds have recently modified their holdings of the business. Public Employees Retirement System of Ohio increased its holdings in PRA Health Sciences by 2,857.2% in the 3rd quarter. Public Employees Retirement System of Ohio now owns 5,944 shares of the medical research company’s stock worth $453,000 after purchasing an additional 5,743 shares in the last quarter. Salem Investment Counselors Inc. bought a new stake in shares of PRA Health Sciences in the 3rd quarter valued at about $315,000. Ameritas Investment Partners Inc. grew its position in shares of PRA Health Sciences by 23.5% in the 3rd quarter. Ameritas Investment Partners Inc. now owns 4,204 shares of the medical research company’s stock valued at $325,000 after buying an additional 800 shares during the last quarter. Neuberger Berman Group LLC grew its position in shares of PRA Health Sciences by 2,738.6% in the 3rd quarter. Neuberger Berman Group LLC now owns 245,711 shares of the medical research company’s stock valued at $18,716,000 after buying an additional 237,055 shares during the last quarter. Finally, South Street Advisors LLC grew its position in shares of PRA Health Sciences by 1.2% in the 3rd quarter. South Street Advisors LLC now owns 109,595 shares of the medical research company’s stock valued at $8,347,000 after buying an additional 1,250 shares during the last quarter. 98.22% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY WARNING: “BidaskClub Downgrades PRA Health Sciences (PRAH) to Buy” was published by Watch List News and is the property of of Watch List News. If you are reading this news story on another website, it was stolen and republished in violation of U.S. and international trademark and copyright legislation. The legal version of this news story can be read at https://www.watchlistnews.com/bidaskclub-downgrades-pra-health-sciences-prah-to-buy/1795476.html.

PRA Health Sciences Company Profile

PRA Health Sciences, Inc is a contract research organization. The Company provides outsourced clinical development services to the biotechnology and pharmaceutical industries. The Company offers therapeutic services in areas of pharmaceutical development, including oncology, central nervous system, inflammation and infectious diseases.

Analyst Recommendations for PRA Health Sciences (NASDAQ:PRAH)

Receive News & Ratings for PRA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.